Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

(2018) Oliver Krenkel et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

Should we undertake surveillance for HCC in patients with NAFLD?

(2018) Ramy Younes et al.   JOURNAL OF HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Targeting hepatic macrophages to treat liver diseases

(2017) Frank Tacke   JOURNAL OF HEPATOLOGY

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

(2017) Vasilios G. Athyros et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Macrophages in Nonalcoholic Fatty Liver Disease: A Role Model of Pathogenic Immunometabolism

(2017) Oliver Krenkel et al.   SEMINARS IN LIVER DISEASE

Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress

(2017) Bing-Hang Li et al.   Translational Research

The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis

(2017) Petra Mulder et al.   PLoS One

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

(2017) Tobias Puengel et al.   PLoS One

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

(2016) Melanie Thompson et al.   AIDS

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

(2016) Tobias Eggert et al.   CANCER CELL

Role of chemokine pathways in hepatobiliary cancer

(2016) Josef Ehling et al.   CANCER LETTERS

CRIg Functions as a Macrophage Pattern Recognition Receptor to Directly Bind and Capture Blood-Borne Gram-Positive Bacteria

(2016) Zhutian Zeng et al.   Cell Host & Microbe

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease

(2016) Sahil Mittal et al.   Clinical Gastroenterology and Hepatology

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

(2016) E Lefebvre et al.   CTS-Clinical and Translational Science

Liver Fibrosis: From Pathogenesis to Novel Therapies

(2016) Ralf Weiskirchen et al.   DIGESTIVE DISEASES

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

(2016) Yaron Rotman et al.   GUT

Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury

(2016) Jana C. Mossanen et al.   HEPATOLOGY

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

(2016) Fabio Piscaglia et al.   HEPATOLOGY

Identification and treatment of the Staphylococcus aureus reservoir in vivo

(2016) Bas G.J. Surewaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy

(2016) Xiang Zhang et al.   JOURNAL OF HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Immunology in the liver — from homeostasis to disease

(2016) Felix Heymann et al.   Nature Reviews Gastroenterology & Hepatology

Management of NAFLD: a stage-based approach

(2016) Mary E. Rinella et al.   Nature Reviews Gastroenterology & Hepatology

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

(2016) Eric Lefebvre et al.   PLoS One

CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis

(2016) Kyoko Tomita et al.   Scientific Reports

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease

(2015) Johannie du Plessis et al.   GASTROENTEROLOGY

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

(2015) Xiaoguang Li et al.   GUT

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis

(2015) Siddharth Singh et al.   HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+monocytes at a site of sterile injury

(2015) Daniela Dal-Secco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

(2015)   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update

(2015) Vasilios G Athyros et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

(2015) Konstantinos Kargiotis   WORLD JOURNAL OF GASTROENTEROLOGY

Roles for Chemokines in Liver Disease

(2014) Fabio Marra et al.   GASTROENTEROLOGY

CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis

(2014) Josef Ehling et al.   GUT

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+macrophage infiltration in mice

(2014) Christer Baeck et al.   HEPATOLOGY

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2

(2012) Kouichi Miura et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status

(2012) H. Kitade et al.   DIABETES

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer

(2012) Carlo Schneider et al.   GUT

Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis

(2012) P. Ramachandran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

(2011) Christer Baeck et al.   GUT

Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice

(2011) Felix Heymann et al.   HEPATOLOGY

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

(2011) Jacob Lalezari et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

C-C Chemokine Receptor 2 Inhibitor Improves Diet-Induced Development of Insulin Resistance and Hepatic Steatosis in Mice

(2011) Yukinori Tamura et al.   Journal of Atherosclerosis and Thrombosis

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

(2011) Tae-Won Kang et al.   NATURE

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

C-C Chemokine Receptor 2 (CCR2) Regulates the Hepatic Recruitment of Myeloid Cells That Promote Obesity-Induced Hepatic Steatosis

(2010) A. E. Obstfeld et al.   DIABETES

The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes

(2010) Karlin Raja Karlmark et al.   HEPATOLOGY

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

(2010) Marie-Luise Berres et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional Contribution of Elevated Circulating and Hepatic Non-Classical CD14+CD16+ Monocytes to Inflammation and Human Liver Fibrosis

(2010) Henning W. Zimmermann et al.   PLoS One

Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis

(2009) Karlin Raja Karlmark et al.   HEPATOLOGY

CCR2 promotes hepatic fibrosis in mice

(2009) Ekihiro Seki et al.   HEPATOLOGY

Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury

(2008) Michael P. Holt et al.   JOURNAL OF LEUKOCYTE BIOLOGY